An Accelerated Progression Relapse Test (APRT) and method is provided for use in the prognosis of a patient having an ER+ breast cancer. The APRT provides a determination of when a patient in a particular diseased state is likely to benefit from further disease treatment, or does not have a high probability of benefit with additional treatment. Four genetic probes are disclosed that target the MKI67, CDC6 and SPAG5 gene and gene products. The ER+ breast cancer patient population is stratified into two groups, with the low gene expression group identifying the patient/patient group that is less likely to benefit from additional treatment measures, and a high gene expression group identifying the patient group that is more likely to benefit from additional treatment measures.
展开▼
机译:提供了加速进展复发测试(APRT)和方法用于患有ER +乳腺癌的患者的预后。 APRT可以确定处于特定疾病状态的患者何时可能会从进一步的疾病治疗中受益,或者何时没有额外的治疗获益的高可能性。公开了四种靶向MKI67,CDC6和SPAG5基因和基因产物的遗传探针。 ER +乳腺癌患者人群分为两组,低基因表达组确定了不太可能从其他治疗措施中受益的患者/患者组,高基因表达组确定了更可能受益于其他治疗措施的患者/患者组受益于其他治疗措施。
展开▼